Because No One is Immune to the Law
December 30, 2020 - FDA, COVID-19, Product Liability + Class Action

FDA’s Covid-19 Product Regulation Enforcement Roadmap

Using Waivers to Curb COVID-19 Legal Exposure

Navigating FDA’s regulatory enforcement strategies is paramount to successfully marketing health and medical products for COVID‑19—especially since the pandemic has dominated FDA’s enforcement activity this year. Understanding the patterns and principles behind FDA’s efforts can provide the insight product manufacturers need to avoid FDA enforcement and let companies know what to expect if they do become the target of enforcement action. To do just that, MoFo’s product regulatory team has tracked and analyzed these enforcement efforts against COVID-19 products to bring you this year‑end guide.

Read more on our Class Dismissed blog